South Korea-based SK Biopharmaceuticals and Swiss Arvelle Therapeutics have signed an exclusive licensing...
- SK Biopharmaceuticals-Arvelle partner on epilepsy drug cenobamate in Europe
- Erectile dysfunction: giving patients more choice and better treatments
- AbCellera and Novartis enter into multi-target partnership
- Dementia Consortium welcomes new partners to drug discovery collaboration
- FDA grants Merck’s Keytruda priority review as first line therapy for HNSCC
FDA accepts Sarepta’s NDA for precision medicine Golodirsen
US precision medicine company Sarepta Therapeutics has announced the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for its Duchenne muscular dystrophy (DMD) drug Golodirsen (SRP-4053).
Medicines Manufacturing Innovation Centre, Renfrewshire
The Centre for Process Innovation (CPI), the University of Strathclyde, Scottish Enterprise, Innovate UK, AstraZeneca and GlaxoSmithKline (GSK) have partnered to open the Medicines Manufacturing Innovation Centre (MMIC) in Renfrewshire, Scotland.
Glenmark Pharmaceuticals to establish new company in US
India-based Glenmark Pharmaceuticals is set to spin-off its innovation business into a new company in the US to increase focus on innovation and advance its pipeline towards commercialisation.
Canadian researchers develop molecules to reverse memory loss
Researchers at Addiction and Mental Health (CAMH) in Canada have developed new therapeutic small molecules that could potentially reverse memory loss caused due to depression and ageing.
SK Biopharmaceuticals-Arvelle partner on epilepsy drug cenobamate in Europe
South Korea-based SK Biopharmaceuticals and Swiss Arvelle Therapeutics have signed an exclusive licensing agreement to develop and commercialise SK Biopharmaceuticals’ cenobamate in Europe.
Erectile dysfunction: giving patients more choice and better treatments
Erectile dysfunction affects around 50% of men between 40 and 70 years old. Futura Medical is currently developing a topical gel product, named MED2005, as a new therapeutic approach for the condition. Can MED2005 add to the treatment choices in the erectile dysfunction space?
AbCellera and Novartis enter into multi-target partnership
Canada-based AbCellera has announced it has signed a multi-year, multi-target agreement with Novartis under which its antibody discovery technology will be leveraged by the Swiss pharma giant for up to ten clinically-relevant disease targets.
Neurogene raises funds to support gene therapy development
Neurogene has secured funding during a Series A financing round to advance the development of its gene therapy candidates intended for the treatment of various neurological diseases.
Dementia Consortium welcomes new partners to drug discovery collaboration
Charity industry partnership Dementia Consortium has announced that pharmaceutical companies, Johnson & Johnson Innovation, Takeda and research organisation Evotec have joined its drug discovery collaboration for neurodegenerative diseases.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.